Cargando…
Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy
Autores principales: | Desaphy, Jean-François, Modoni, Anna, LoMonaco, Mauro, Camerino, Diana Conte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621996/ https://www.ncbi.nlm.nih.gov/pubmed/23052413 http://dx.doi.org/10.1007/s00228-012-1414-3 |
Ejemplares similares
-
Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation
por: Desaphy, Jean-François, et al.
Publicado: (2016) -
Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes()
por: Desaphy, Jean-François, et al.
Publicado: (2013) -
Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias
por: Modoni, Anna, et al.
Publicado: (2020) -
In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia
por: Desaphy, Jean-François, et al.
Publicado: (2013) -
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs
por: Desaphy, Jean-François, et al.
Publicado: (2014)